Literature DB >> 30817276

Comparison of outcomes in malignant vs. non-malignant ischemic priapism: 12-year experience from a tertiary center.

Manoj Kumar1, Gaurav Garg1, Ashish Sharma1, Siddharth Pandey1, Manmeet Singh1, Satya Narayan Sankhwar1.   

Abstract

OBJECTIVE: Data on outcome of patients with ischemic priapism (IP) due to malignant causes are scant. In this study, we compared outcome of patients with malignant vs. non-malignant IP in adult North Indian men.
MATERIAL AND METHODS: We analyzed medical records of patients with IP who presented to a large tertiary care referral center from August 2005 to July 2017.
RESULTS: Data of 71 patients were analyzed. The median age was 30 years (range 17-65). The average duration of symptoms was 4.39 days (range 1-10). Most common etiology was idiopathic in 29 (40.84%), chronic myeloid leukemia (CML) in 24 (33.80%), and drug-induced in 15 patients. Thirty-eight patients underwent distal shunts, while nine patients underwent proximal shunt procedure. Men with malignant priapism (CML) had significantly lower success rates with interventions, prolonged hospital stay, and higher complications (p<0.05). Most complications after shunt surgery were minor (Clavein grade 1 and 2). After shunt surgery, bleeding at shunt site was observed in 14 cases, and wound infection developed in five patients. Prevalence of erectile dysfunction in patients at follow-up was high.
CONCLUSION: Men with malignant priapism (CML) had significantly lower success rates with interventions, prolonged hospital stay, and higher complications than men with non-malignant priapism.

Entities:  

Year:  2019        PMID: 30817276      PMCID: PMC6739082          DOI: 10.5152/tud.2019.75044

Source DB:  PubMed          Journal:  Turk J Urol        ISSN: 2149-3235


  29 in total

1.  The management of low-flow priapism with the immediate insertion of a penile prosthesis.

Authors:  R W Rees; J Kalsi; S Minhas; J Peters; P Kell; D J Ralph
Journal:  BJU Int       Date:  2002-12       Impact factor: 5.588

2.  American Urological Association guideline on the management of priapism.

Authors:  Drogo K Montague; Jonathan Jarow; Gregory A Broderick; Roger R Dmochowski; Jeremy P W Heaton; Tom F Lue; Ajay Nehra; Ira D Sharlip
Journal:  J Urol       Date:  2003-10       Impact factor: 7.450

3.  Cocaine associated priapism.

Authors:  A L Altman; A D Seftel; S L Brown; N Hampel
Journal:  J Urol       Date:  1999-06       Impact factor: 7.450

4.  Low-flow priapism: risk factors for erectile dysfunction.

Authors:  M S El-Bahnasawy; A Dawood; A Farouk
Journal:  BJU Int       Date:  2002-02       Impact factor: 5.588

5.  Priapism in adult Nigerians.

Authors:  A E Aghaji
Journal:  BJU Int       Date:  2000-03       Impact factor: 5.588

Review 6.  Priapism: pathogenesis, epidemiology, and management.

Authors:  Gregory A Broderick; Ates Kadioglu; Trinity J Bivalacqua; Hussein Ghanem; Ajay Nehra; Rany Shamloul
Journal:  J Sex Med       Date:  2010-01       Impact factor: 3.802

7.  The immediate insertion of a penile prosthesis for acute ischaemic priapism.

Authors:  David J Ralph; Giulio Garaffa; Asif Muneer; Alex Freeman; Rowland Rees; Andrew N Christopher; Sukbinder Minhas
Journal:  Eur Urol       Date:  2008-10-01       Impact factor: 20.096

Review 8.  Medical and surgical management of priapism.

Authors:  J Cherian; A R Rao; A Thwaini; F Kapasi; I S Shergill; R Samman
Journal:  Postgrad Med J       Date:  2006-02       Impact factor: 2.401

Review 9.  Therapy insight: Priapism associated with hematologic dyscrasias.

Authors:  Arthur L Burnett
Journal:  Nat Clin Pract Urol       Date:  2005-09

10.  Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.

Authors:  Daniel Dindo; Nicolas Demartines; Pierre-Alain Clavien
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

View more
  1 in total

Review 1.  Malignant Priapism - What Do We Know About It?

Authors:  Dragos Marcu; Lucian Iorga; Dan Mischianu; Nicolae Bacalbasa; Irina Balescu; Ovidiu Bratu
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.